2型糖尿病强化血糖控制随机对照试验的试验后监测从10年延长至24年(UKPDS 91)
UKPDS 91在20年干预试验及10年试验后监测基础上,将1525名存活参与者中的1489人(97.6%)通过NHS常规数据再延长随访14年(至2021年9月30日),总随访人年从66972增至80724(增加21%)。与常规血糖控制相比,早期强化血糖控制(磺脲类或胰岛素)使全因死亡相对风险降低10%(95%CI 2-17;p=0.015)、心肌梗死降低17%(6-26;p=0.002)、微血管病变降低26%(14-36;p<0.0001),绝对风险降低分别为2.7%、3.3%、3.5%。早期二甲双胍强化治疗使全因死亡相对风险降低20%(95%CI 5-32;p=0.010)、心肌梗死降低31%(12-46;p=0.003),绝对风险降低分别为4.9%和6.2%。两种强化策略均未观察到卒中或周围血管疾病的显著风险降低,二甲双胍也未观察到微血管病变的显著降低。作者认为,确诊后立即达到接近血糖正常可能对最大限度减少终身糖尿病相关并发症风险至关重要。
要点
- 早期磺脲类/胰岛素强化血糖控制 vs 常规控制:全因死亡相对风险降低10%(95%CI 2-17;p=0.015),绝对风险降低2.7%。
- 早期磺脲类/胰岛素强化血糖控制 vs 常规控制:心肌梗死相对风险降低17%(95%CI 6-26;p=0.002),绝对风险降低3.3%;微血管病变降低26%(95%CI 14-36;p<0.0001),绝对风险降低3.5%。
- 早期二甲双胍强化治疗 vs 常规控制:全因死亡相对风险降低20%(95%CI 5-32;p=0.010),绝对风险降低4.9%;心肌梗死降低31%(95%CI 12-46;p=0.003),绝对风险降低6.2%。
- 两种强化策略均未观察到卒中或周围血管疾病的显著风险降低;二甲双胍未观察到微血管病变的显著风险降低。
- 作者认为,确诊后立即达到接近血糖正常可能对最大限度减少终身糖尿病相关并发症风险至关重要。
适用人群与场景
- 1977年至1991年间入组、新诊断2型糖尿病的5102例患者中,4209例(82.5%)被随机分配至强化血糖控制(磺脲类或胰岛素,超重者用二甲双胍)或常规血糖控制(主要为饮食)。
- 20年干预试验结束时存活的3277例参与者进入10年试验后监测期(至2007年9月30日);本研究纳入该10年监测期结束时所有存活参与者,最终1525例中1489例(97.6%)可链接至NHS常规行政数据。
研究设计与关键结果
- 研究类型:对UKPDS随机对照试验的试验后延长随访(试验后监测),通过链接NHS常规收集的死亡、住院、门诊和急诊就诊记录获取临床结局;采用Kaplan-Meier时间-事件分析和log-rank检验,按意向性治疗分析7项预设复合临床结局。
- 随访:2007年10月1日至2021年9月30日延长随访14年;基线平均年龄50.2岁(SD 8.0),女性41.3%;2021年9月30日仍存活者平均年龄79.9岁(SD 8.0);自基线个体随访0至42年,中位17.5年(IQR 12.3-26.8);总随访人年从66972增至80724(增加21%)。
- 磺脲类或胰岛素强化血糖控制 vs 常规控制:全因死亡相对风险降低10%(95%CI 2-17;p=0.015),绝对风险降低2.7%;心肌梗死相对风险降低17%(95%CI 6-26;p=0.002),绝对风险降低3.3%;微血管病变相对风险降低26%(95%CI 14-36;p<0.0001),绝对风险降低3.5%。
- 二甲双胍强化治疗 vs 常规控制:全因死亡相对风险降低20%(95%CI 5-32;p=0.010),绝对风险降低4.9%;心肌梗死相对风险降低31%(95%CI 12-46;p=0.003),绝对风险降低6.2%。
- 两种强化血糖控制组在试验期间及试验后均未观察到卒中或周围血管疾病的显著风险降低;二甲双胍治疗未观察到微血管病变的显著风险降低。
证据类型、等级与局限
- 证据类型:随机对照试验的长期试验后监测(延长随访),研究注册号ISRCTN75451837。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,早期强化血糖控制(磺脲类或胰岛素,或二甲双胍)与常规血糖控制相比,似乎可带来接近终身的死亡和心肌梗死风险降低。
- 作者认为,确诊后立即达到接近血糖正常可能对最大限度减少终身糖尿病相关并发症风险至关重要。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The 20-year UK Prospective Diabetes Study showed major clinical benefits for people with newly diagnosed type 2 diabetes randomly allocated to intensive glycaemic control with sulfonylurea or insulin therapy or metformin therapy, compared with conventional glycaemic control. 10-year post-trial follow-up identified enduring and emerging glycaemic and metformin legacy treatment effects. We aimed to determine whether these effects would wane by extending follow-up for another 14 years.
METHODS: 5102 patients enrolled between 1977 and 1991, of whom 4209 (82·5%) participants were originally randomly allocated to receive either intensive glycaemic control (sulfonylurea or insulin, or if overweight, metformin) or conventional glycaemic control (primarily diet). At the end of the 20-year interventional trial, 3277 surviving participants entered a 10-year post-trial monitoring period, which ran until Sept 30, 2007. Eligible participants for this study were all surviving participants at the end of the 10-year post-trial monitoring period. An extended follow-up of these participants was done by linking them to their routinely collected National Health Service (NHS) data for another 14 years. Clinical outcomes were derived from records of deaths, hospital admissions, outpatient visits, and accident and emergency unit attendances. We examined seven prespecified aggregate clinical outcomes (ie, any diabetes-related endpoint, diabetes-related death, death from any cause, myocardial infarction, stroke, peripheral vascular disease, and microvascular disease) by the randomised glycaemic control strategy on an intention-to-treat basis using Kaplan-Meier time-to-event and log-rank analyses. This study is registered with the ISRCTN registry, number ISRCTN75451837.
FINDINGS: Between Oct 1, 2007, and Sept 30, 2021, 1489 (97·6%) of 1525 participants could be linked to routinely collected NHS administrative data. Their mean age at baseline was 50·2 years (SD 8·0), and 41·3% were female. The mean age of those still alive as of Sept 30, 2021, was 79·9 years (SD 8·0). Individual follow-up from baseline ranged from 0 to 42 years, median 17·5 years (IQR 12·3-26·8). Overall follow-up increased by 21%, from 66 972 to 80 724 person-years. For up to 24 years after trial end, the glycaemic and metformin legacy effects showed no sign of waning. Early intensive glycaemic control with sulfonylurea or insulin therapy, compared with conventional glycaemic control, showed overall relative risk reductions of 10% (95% CI 2-17; p=0·015) for death from any cause, 17% (6-26; p=0·002) for myocardial infarction, and 26% (14-36; p<0·0001) for microvascular disease. Corresponding absolute risk reductions were 2·7%, 3·3%, and 3·5%, respectively. Early intensive glycaemic control with metformin therapy, compared with conventional glycaemic control, showed overall relative risk reductions of 20% (95% CI 5-32; p=0·010) for death from any cause and 31% (12-46; p=0·003) for myocardial infarction. Corresponding absolute risk reductions were 4·9% and 6·2%, respectively. No significant risk reductions during or after the trial for stroke or peripheral vascular disease were observed for both intensive glycaemic control groups, and no significant risk reduction for microvascular disease was observed for metformin therapy.
INTERPRETATION: Early intensive glycaemic control with sulfonylurea or insulin, or with metformin, compared with conventional glycaemic control, appears to confer a near-lifelong reduced risk of death and myocardial infarction. Achieving near normoglycaemia immediately following diagnosis might be essential to minimise the lifetime risk of diabetes-related complications to the greatest extent possible.
FUNDING: University of Oxford Nuffield Department of Population Health Pump Priming.
参考来源
- Adler AI, Coleman RL, Leal J, et al. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024. PMID: 38772405. doi:10.1016/S0140-6736(24)00537-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。